Download PDF
CC BY-NC-ND 4.0 · TH Open 2017; 01(01): e33-e42
DOI: 10.1055/s-0037-1603924
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE

Walter Ageno
1   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Lorenzo G. Mantovani
2   CESP-Center for Public Health Research, University of Milan Bicocca, Monza, Italy
,
Sylvia Haas
3   Technical University of Munich, Munich, Germany
,
Reinhold Kreutz
4   Institute of Clinical Pharmacology and Toxicology, Charité Universitätsmedizin, Berlin, Germany
,
Danja Monje
5   Bayer AG, Leverkusen, Germany
,
Jonas Schneider
6   Bayer AG, Berlin, Germany
,
Martin van Eickels
6   Bayer AG, Berlin, Germany
,
Martin Gebel
7   Bayer AG, Wuppertal, Germany
,
Alexander G. G. Turpie
8   Department of Medicine, Hamilton Health Sciences, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2017 (online)

   Permissions and Reprints

Abstract

Background The noninterventional XALIA study compared rivaroxaban with standard anticoagulation for deep vein thrombosis treatment. This substudy describes the demographics, clinical characteristics, and outcomes of the patients with cancer.

Methods Therapy type, dose, and duration were at the physician's discretion. The cohorts identified were rivaroxaban (rivaroxaban alone or after heparin or fondaparinux for ≤48 hours); early switchers (rivaroxaban after heparin or fondaparinux for >48 hours to 14 days and/or a vitamin K antagonist [VKA] for 1–14 days); standard anticoagulation (heparin or fondaparinux and a VKA); low-molecular-weight heparin (LMWH) alone; and miscellaneous (other heparins, fondaparinux alone, VKA alone). Primary outcomes were major bleeding, recurrent venous thromboembolism, and all-cause mortality.

Results In XALIA, 587 patients (11.4% of the XALIA cohort) were with cancer: 146 (24.9%) rivaroxaban, 30 (5.1%) early switchers, 141 (24.0%) standard anticoagulation, 223 (38.0%) LMWH, and 47 (8.0%) miscellaneous. Patients with gastrointestinal or lung cancer more commonly received LMWH than rivaroxaban; the opposite occurred in patients with breast or genitourinary cancer. Rates of primary outcome in the rivaroxaban group were as follows: major bleeding, 1.4% (n = 2); recurrent venous thromboembolism, 3.4% (n = 5); and all-cause mortality, 4.8% (n = 7).

Conclusion In XALIA, physicians treated cancer-associated thrombosis with various anticoagulant regimens, most commonly LMWH. In addition, the choice of anticoagulant varied with cancer type. In rivaroxaban-treated patients, rates for the primary outcomes were low, suggesting that patients administered rivaroxaban were a good prognosis group.

Keywords

cancer-associated thrombosis - low-molecular-weight heparin - rivaroxaban - routine clinical practice - venous thromboembolism

Contributions of Authors

W.A. created the initial draft of this report. W.A., L.G.M., S.H., R.K., and A.G.G.T. were members of the Adjudication Committee. M.G. performed the statistical analysis. All authors participated in writing and review of the report and accept full responsibility for its overall content.


Funding

Funding for this study was provided by Bayer AG and Janssen Scientific Affairs, LLC.


Trial Registration Number

NCT01619007.


 

  • References

  • 1 Young A, Chapman O, Connor C, Poole C, Rose P, Kakkar AK. Thrombosis and cancer. Nat Rev Clin Oncol 2012; 9 (08) 437-449
    CrossrefPubMedGoogle Scholar
  • 2 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300 (19) 2277-2285
    CrossrefPubMedGoogle Scholar
  • 3 Moore RA, Adel N, Riedel E. , et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29 (25) 3466-3473
    CrossrefPubMedGoogle Scholar
  • 4 Tully CM, Apolo AB, Zabor EC. , et al. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer 2016; 122 (05) 712-721
    CrossrefPubMedGoogle Scholar
  • 5 Louzada ML, Majeed H, Wells PS. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009; 123 (06) 837-844
    CrossrefPubMedGoogle Scholar
  • 6 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 7 Piatek C, O'Connell CL, Liebman HA. Treating venous thromboembolism in patients with cancer. Expert Rev Hematol 2012; 5 (02) 201-209
    CrossrefPubMedGoogle Scholar
  • 8 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 9 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 10 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 11 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 12 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 13 Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (02) 475-483
    CrossrefPubMedGoogle Scholar
  • 14 Prins MH, Lensing AWA, Brighton TA. , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (01) e37-e46
    PubMedGoogle Scholar
  • 15 Ageno W, Mantovani LG, Haas S. , et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 3 (01) e12-e21
    PubMedGoogle Scholar
  • 16 Zangari M, Anaissie E, Barlogie B. , et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98 (05) 1614-1615
    CrossrefPubMedGoogle Scholar
  • 17 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedGoogle Scholar
  • 18 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110 (10) 2339-2346
    CrossrefPubMedGoogle Scholar
  • 19 Prandoni P, Lensing AWA, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 20 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 (17) 3078-3083
    CrossrefPubMedGoogle Scholar
  • 21 Ageno W, Mantovani LG, Haas S. , et al. Real life studies and good clinical practice - Authors' reply. Lancet Haematol 2016; 3 (04) e160-e161
    PubMedGoogle Scholar